Velafermin Shows Promising Results in Prevention of Chemotherapy Induced Oral mucositis
May 18, 2005 - 9:37:00 AM
|
|
|
"In addition to exploring the efficacy of a single-dose of velafermin for the prevention of OM, we are also evaluating the safety of velafermin in a Phase I study for the treatment of active OM, specifically in patients who develop OM as a result of the chemotherapy they receive for the treatment of their cancer."
|
By CuraGen Corporation,
[RxPG] CuraGen Corporation today announced that Michael W. Schuster, M.D., Principal Investigator, Professor of Clinical Medicine in the Division of Hematology/Oncology at the Weill Medical College of Cornell University, and Director of Stem Cell Transplantation at NewYork-Presbyterian Hospital/Weill Cornell Medical Center presented the final Phase I results for a single-dose of velafermin (CG53135) for the prevention of oral mucositis (OM) in patients receiving high dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (AHSCT) at the American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, FL.
The final results from this Phase I study suggest velafermin (CG53135) is well tolerated following intravenous administration with data supporting the Company's ongoing Phase II trial and strategy of investigating a single-dose of velafermin (CG53135) for the prevention of OM.
"Based on our experience with velafermin in Phase I, we are pleased to be taking part in the Phase II trial to evaluate this investigational drug for the prevention of OM," stated Michael W. Schuster, M.D. "Oral mucositis is a severe side effect that frequently occurs as a result of the high-dose chemotherapy administered to patients prior to bone marrow transplantation. Fibroblast growth factors, including velafermin, represent a new class of drugs that show promise for potentially avoiding or ameliorating OM and avoiding complications associated with this condition, such as pain and infection, and improving patients' quality of life."
"As we continue to advance velafermin through Phase II, we are pleased with the progress being made in the program and remain on track to complete this trial during the first half of 2006," stated Timothy M. Shannon, M.D., Executive Vice President of Research and Development and Chief Medical Officer at CuraGen. "In addition to exploring the efficacy of a single-dose of velafermin for the prevention of OM, we are also evaluating the safety of velafermin in a Phase I study for the treatment of active OM, specifically in patients who develop OM as a result of the chemotherapy they receive for the treatment of their cancer."
Data on 30 patients dosed with velafermin (CG53135) were presented in a poster entitled, "Phase I Trial of CG53135-05 (Velafermin) to Prevent Mucositis in Patients Undergoing High-dose Chemotherapy (HDCT) and Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)." Primary objectives for the study were the evaluation of safety, tolerability, and pharmacokinetics following a single-dose of velafermin (CG53135). As a secondary objective, the study assessed the development of OM using the WHO OM assessment scale. Patients received a single-dose of 0.03, 0.1, 0.2, or 0.33 mg/kg velafermin (CG53135) administered intravenously one day after infusion of blood stem cells following high-dose chemotherapy.
Of the 30 patients (male = 21, female = 9) presented in this poster, the median age was 55 years (range 25-75) with diagnoses including multiple myeloma (n=16), non-Hodgkin's lymphoma (n=12), acute myelogenous leukemia (n=1) and desmoplasmic round cell tumor (n=1). High-dose chemotherapy conditioning regimens included high-dose melphalan (Mel 200), carboplatin and thiotepa, cyclophosphamide, carmustine, and etoposide, and busulfan and cyclophosphamide. No serious drug-related adverse events were noted following treatment with velafermin (CG53135). Mild to moderate reactions including nausea, vomiting, tachycardia, hypotension, chills, and fever were observed. Following administration of a single-dose of velafermin (CG53135), 22 of 30 patients (73%) did not develop severe grade 3 or 4 OM.
Based on results from Phase I, the 0.03, 0.1 and 0.2 mg/kg single doses of velafermin (CG53135) are currently being evaluated in a randomized, double- blind, placebo-controlled, multi-center Phase II clinical trial for the prevention of OM in approximately 200 patients receiving HDCT followed by AHSCT. This trial is expected to be complete during the first half of 2006.
Background on Velafermin (CG53135) and OM
Velafermin (CG53135), a novel fibroblast growth factor discovered by CuraGen that appears to promote both epithelial and mesenchymal cell proliferation, is currently being investigated for the prevention and treatment of OM, a side effect experienced by cancer patients undergoing chemotherapy or radiation therapy.
The disease is characterized by inflammation and ulceration of the tissue lining the mouth and throat, leading to bleeding, pain, and difficulty eating and drinking. OM is sometimes a cause for clinicians to interrupt patients' cancer treatment regimens, thus limiting the success of therapeutic plans. Velafermin (CG53135) is being investigated for the prevention of OM by being administered to patients before the onset of symptoms in order to decrease the incidence and duration of the disease.
Animal studies suggest that velafermin (CG53135) may also be effective for the treatment of OM when it is administered after the onset of early signs of OM in order to decrease the duration and progression to severe OM. An effective therapy for OM has the potential to treat debilitating symptoms, to allow cancer patients to better tolerate the appropriate doses of cancer treatment, and to decrease hospitalization time.
Publication:
The Results were Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, FL
On the web:
www.curagen.com 
|
Advertise in this space for $10 per month.
Contact us today.
|
 |
|
Subscribe to Therapy Newsletter
|
|
|
|
Additional information about the news article
|
Reprints of the poster presentation and published abstracts, as well as information about ongoing clinical trials are available on the Company's website, http://www.curagen.com, or by emailing [email protected]
About CuraGen
CuraGen Corporation (Nasdaq: CRGN - News) is a genomics-based pharmaceutical company dedicated to improving the lives of patients by developing a pipeline of novel protein, antibody, and small molecule therapeutics in the areas of oncology, inflammatory diseases, and diabetes. CuraGen has established broad development alliances with Abgenix, TopoTarget, and Bayer, and its experienced preclinical and clinical teams are advancing the Company's pipeline of products for unmet medical needs. CuraGen's technology and expertise have been used in partnerships with more than a dozen leading biotechnology and pharmaceutical companies including Bayer, Biogen, Genentech, GlaxoSmithKline, Hoffmann-La Roche and Pfizer. The Company is headquartered in New Haven, CT and additional information is available at http://www.curagen.com.
Safe Harbor
This press release contains forward-looking statements including statements about the potential for fibroblast growth factors, including velafermin (CG53135), to avoid or ameliorate OM and avoid complications associated with this condition and improving patients' quality of life; CuraGen's expectation that it will advance velafermin (CG53135) through Phase II and that this trial will be complete during the first half of 2006; and the potential for an effective therapy for OM to treat debilitating symptoms, to allow cancer patients to better tolerate the appropriate doses of cancer treatment, and to decrease hospitalization time. We caution investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: the risk that any one or more of the drug development programs of CuraGen will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; CuraGen's history of incurring losses and the uncertainty of achieving profitability; CuraGen's stage of development as a genomics-based pharmaceutical company; government regulation; patent infringement claims against CuraGen's products, processes and technologies; the ability to protect CuraGen's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability exposure. Please refer to CuraGen's Annual Report on Form 10-K for the period ended December 31, 2004 for a complete description of these risks. CuraGen disclaims any intention or obligation to update or revise any forward- looking statements, whether as a result of new information, future events, or otherwise, unless required by law.
CuraGen Contact:
Glenn Schulman, Pharm.D.
[email protected]
(888) GENOMICS
|
|
Feedback
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
|
Top of Page
|
